Unknown

Dataset Information

0

A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells.


ABSTRACT: Monoclonal antibodies directed to the B-cell-specific CD20-antigen are successfully used for the treatment of lymphomas and autoimmune diseases. Here, we compare the anti-B-cell activity of three different antibodies directed to CD20: (i) a chimeric, monospecific antibody, (ii) an Fc-optimized variant thereof, and (iii) a bispecific CD20×CD95-antibody in a newly developed recombinant format, termed Fabsc. The bispecific antibody specifically triggers the CD95 death receptor on malignant, as well as activated, normal B-cells. We found that the capability of this antibody to suppress the growth of malignant B-cells in vitro and in vivo and to specifically deplete normal, activated B-cells from peripheral blood mononuclear cell (PBMC) cultures was superior to that of the Fc-optimized monospecific antibody. This antibody in turn was more effective than its nonoptimized variant. Moreover, the bispecific antibody was the only reagent capable of significantly suppressing antibody production in vitro. Our findings imply that the bispecific CD20×CD95-antibody might become a new, prototypical reagent for the treatment of B-cell-mediated autoimmune disease.

SUBMITTER: Nalivaiko K 

PROVIDER: S-EPMC4817817 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells.

Nalivaiko Kristina K   Hofmann Martin M   Kober Karina K   Teichweyde Nadine N   Krammer Peter H PH   Rammensee Hans-Georg HG   Grosse-Hovest Ludger L   Jung Gundram G  

Molecular therapy : the journal of the American Society of Gene Therapy 20151119 2


Monoclonal antibodies directed to the B-cell-specific CD20-antigen are successfully used for the treatment of lymphomas and autoimmune diseases. Here, we compare the anti-B-cell activity of three different antibodies directed to CD20: (i) a chimeric, monospecific antibody, (ii) an Fc-optimized variant thereof, and (iii) a bispecific CD20×CD95-antibody in a newly developed recombinant format, termed Fabsc. The bispecific antibody specifically triggers the CD95 death receptor on malignant, as well  ...[more]

Similar Datasets

| S-EPMC5548338 | biostudies-literature
| S-EPMC2585743 | biostudies-literature
| S-EPMC4026529 | biostudies-literature
| S-EPMC5418113 | biostudies-literature
| S-EPMC7892878 | biostudies-literature
| S-EPMC4933590 | biostudies-literature
| S-EPMC4623422 | biostudies-literature
| S-EPMC5749665 | biostudies-literature
| S-EPMC8671946 | biostudies-literature
| S-EPMC8164134 | biostudies-literature